Laurus Labs Share Price Target 2026 To 2030

In this article, we will analyze Laurus Labs Share Price Target 2026 by reviewing the company’s business growth, financial performance, future expansion plans, and potential returns for investors.

Laurus Labs is a Hyderabad-based pharma company that mainly works in:

• API (Active Pharmaceutical Ingredients) → raw ingredients used to make medicines
• Formulations (FDF) → finished medicines/tablets
• CDMO/Custom Synthesis → manufacturing drugs for global pharma companies
• Biotech segment → newer growth area

It was founded in 2005 by Dr. Satyanarayana Chava.

Laurus Labs Ltd – About Company

The company Laurus Labs Ltd operates through multiple business segments such as Generic APIs, Finished Dosage Formulations (FDF), CDMO (Contract Development and Manufacturing Organization), and Biotechnology. It manufactures medicines used in areas like HIV treatment, oncology, cardiovascular diseases, diabetes, and gastro-related treatments. Its CDMO business is growing quickly because many global pharma companies outsource drug manufacturing work to Laurus Labs.

Laurus Labs has built strong manufacturing capabilities with multiple plants located in Visakhapatnam, Hyderabad, and Bengaluru, along with several R&D centers.

The company has received approvals from major global regulators like the USFDA, WHO, MHRA, and KFDA, which helps it sell products internationally.

In recent years, Laurus Labs has been focusing on becoming a high-growth pharmaceutical company by expanding its CDMO and biotech business.

Financial Performance of Company

Laurus Labs has shown strong recovery after weak years:

• Q1 FY26 revenue grew 31% YoY to around ₹1,570 crore
• Net profit jumped over 1,100% YoY
• CDMO revenue grew strongly due to new contracts

In Q2 FY26:

• Revenue rose 35%
• Profit increased 875% YoY to ₹195 crore

In Q3 FY26:

• Revenue grew 26%
• Margins improved
• Stock surged due to strong growth expectations

Laurus Labs Share Price Target 2026

Months	Minimum Price  (Rs)	Maximum Price  (Rs)
January	955/-	1,010/-
February	1,050/-	1,070/-
March	970/-	990/-
April	1,120/-	1,130/-
May	1,135/-	1,140/-
June	1,145/-	1,150/-
July	1,125/-	1,145/-
August	1,150/-	1,160/-
September	1,170/-	1,174/-
October	1,178/-	1,179/-
November	1,179/-	1,190/-
December	1,200/-	1,270/-

Laurus Labs Share Price Target 2027

Months	Minimum Price  (Rs)	Maximum Price  (Rs)
2027	1,350/-	1,450/-

Laurus Labs Share Price Target 2028

Months	Minimum Price  (Rs)	Maximum Price  (Rs)
2027	1,500/-	1,700/-

Laurus Labs Share Price Target 2029

Months	Minimum Price  (Rs)	Maximum Price  (Rs)
2027	1,800/-	2,300/-

Laurus Labs Share Price Target 2030

Months	Minimum Price  (Rs)	Maximum Price  (Rs)
2027	3,000/-	3,200/-

Is Laurus Labs a good stock to buy?

Laurus Labs looks like a good company, but at current price levels it may not be the safest fresh buy.

The positive side is very strong right now. The company’s business recovery is real—Q3 FY26 revenue grew 26% YoY to ₹1,778 crore, while net profit jumped 174% YoY to ₹252 crore, mainly because of strong growth in its CDMO business, API recovery, and improving margins.

Its long-term story is also attractive because Laurus is expanding into:

• CDMO (big growth opportunity)
• Biotech
• High-value APIs
• New manufacturing capacity

This is why investors are bullish on the stock.

But the biggest concern is valuation.

The stock has already rallied heavily and is trading near ₹1,100+ levels / all-time highs, while its P/E is around 70+, which is quite expensive compared to many pharma companies.

Even some valuation models suggest the stock may currently be overvalued compared to estimated fair value.

My simple view:

✅ Good stock for long-term watchlist

✅ Existing investors can consider holding if they entered at lower levels

⚠️ Fresh investors should avoid chasing after a huge rally

⚠️ Better to wait for corrections or more earnings growth before entering

If you are investing for 3–5 years, Laurus Labs can still do well because the business quality is improving. But for short-term buying at current highs, risk is also higher.

Simple verdict: Great company, good long-term story, but current valuation looks expensive—wait for better entry if you’re a new investor.

Some Risk in Laurus Labs Stock?

⚠️ High valuation (P/E around 70+ currently)

⚠️ If CDMO growth slows, stock may correct

⚠️ Pharma sector faces USFDA/regulatory risks

⚠️ Heavy dependence on execution of new projects

What is the next target of Laurus Labs?

Laurus Labs does not have a fixed “next target” because stock prices move based on company performance, market sentiment, and overall market conditions. However, based on recent trends and analyst expectations, the stock could see its next short-term target in the ₹1,180 to ₹1,280 range if it continues its strong upward momentum. The company has recently delivered impressive revenue and profit growth, mainly driven by its fast-growing CDMO business and improving margins, which has increased investor confidence.

In the long term, Laurus Labs could move even higher if the company continues expanding its pharmaceutical business, secures more global contracts, and maintains strong earnings growth. Its focus on high-growth segments such as CDMO, biotechnology, and specialty drug manufacturing makes it a promising company for future growth. If these business expansions perform well, the stock may attract more long-term investors.

However, investors should also be careful because the stock has already risen significantly in recent months and is trading near higher valuation levels. If quarterly earnings slow down, market sentiment weakens, or the broader market corrects, the stock may face short-term pressure and could fall toward support levels before moving higher again.

Overall, Laurus Labs remains a strong long-term growth stock, but its next price target will largely depend on future earnings performance, business expansion success, and overall stock market conditions.

Is Laurus Labs debt free?

As per its latest available financials (March 2025 balance sheet), the company had total debt of roughly ₹2,700–2,990 crore.

Debt has actually increased over the last few years because Laurus Labs invested heavily in:

• expanding its CDMO business
• new manufacturing plants
• biotech expansion
• fermentation projects
• future growth capex

Its debt trend looks like this:

• Mar 2021: ₹1,453 crore
• Mar 2022: ₹1,732 crore
• Mar 2023: ₹1,972 crore
• Mar 2024: ₹2,507 crore
• Mar 2025: ₹2,693 crore+

But this is important: having debt doesn’t automatically mean bad company.

Laurus took debt mainly for expansion, and now its profits are improving strongly because CDMO revenue is growing fast. If earnings continue rising, the company can reduce debt over time.

What investors should watch:

✅ Debt-to-equity ratio (should stay controlled)
✅ Interest coverage ratio
✅ Free cash flow
✅ Whether new capex starts generating strong returns

Simple verdict: Laurus Labs is not debt-free, but its debt is currently manageable if growth continues. The main risk would be if profits slow down while debt remains high.

In conclusion, Laurus Labs Share Price Target 2026 looks promising due to the company’s strong presence in the pharmaceutical sector, growing CDMO business, and improving financial performance. While short-term market fluctuations may create volatility, Laurus Labs has solid long-term growth potential if it continues expanding its operations and maintaining strong earnings growth. Investors should always research properly and consider market risks before making any investment decision.

Freqentely Asked Question’s